Skip to content

Earnings call

Lupin Q4 FY26 earnings call: Lupin expects high-single digit overall sales growth and an EBITDA margin around 25% or in the vicinity of that for the full year

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company expects high-single digit overall sales growth and an EBITDA margin around 25% or in the vicinity of that for the full year. Biosimilar franchise revenue is about USD 50 million right now and is slated to be multiple times this financial year. The company will amortize USD 75 million over the next two years.

The numbers management gave

Results

  • Biosimilar franchise revenue is about USD 50 million right now and is slated to be multiple times this financial year.
    Show source
    Nilesh Gupta: It’s about USD 50 million right now but slated to be multiple times this financial year itself.
  • The company has factored the additional cost per unit into its Gross margin going forward.
    Show source
    Vinita Gupta: And we have factored in the additional cost per unit in our Gross margin going forward.

Money and capital

  • The company will amortize USD 75 million over the next two years.
    Show source
    The amortization of the USD 75 million will be in the next two years .

What it expects ahead

What management expects

  • The company expects high-single digit overall sales growth and an EBITDA margin around 25% or in the vicinity of that for the full year.
    Show source
    We did say that we would be looking at around about 25%, or in the vicinity of that for the full year and of course high-single digit number in terms of overall sales growth.
  • The company expects Tolvaptan and Mirabegron to be material contributors in FY27, while generic penetration is under 40% for Tolvaptan and just reaching 50% for Mirabegron, creating potential for further generic penetration and marketplace expansion despite additional competition.
    Show source
    So, we do expect them to be material contributors especially in FY27.
  • The company filed a material 505(b)(2) Apixaban new dosage form with the agency and expects it to come to market in FY28.
    Show source
    We expect that to come to the market in FY28.
  • Goal is to be a Top 3 player in generic Semaglutide, and it said it was well on track toward that goal.
    Show source
    But, I think our goal is very clear to be at Top 3 player in this as generic Semaglutide and I think we're well on track.
  • The company expects Ravicti® (Glycerol Phenylbutyrate (“GPB”)) to be a material product in FY27.
    Show source
    Apart from that, I think in th e next fiscal year, o ur Ravicti® product, the Glycerol Phenylbutyrate (“ GPB”) is a material product for us in FY27.
  • The company hopes to launch Saxenda® in the second half of the year, when it would be a material product.
    Show source
    We have Saxenda® that we hope to launch in the second half of the year, which would Page 8 of 18 May 8, 2026 be a material product for us.
Show 12 more statements

What management expects

  • The company expects Pegfilgrastim to start ramping up from Q2 and Q3 onwards and to be a material contributor to FY27, following its partnership with Valorum.
    Show source
    We've just entered into partnership with Valorum and expect that from Q2 and Q3 onwards will start ramping up and be a material contributor to the fiscal year.
  • The company expects the full-year impact of Pegfilgrastim and Ranibizumab, which it expects to launch later in FY27, to be a material opportunity in FY28.
    Show source
    That should be a material opportunity for us in FY28.
  • The company is in the final stages with Dulera, responding to the FDA's last query, and expects the product to be on the market in FY28.
    Show source
    We are in the final stages with Dulera at this point, just responding to the last query from the FDA and would expect that product to be in the market in FY28 plus we have a material 505(b)(2) Apixaban new dosage form that we filed to the agency.
  • The company expects VISUfarma's ophthalmology business to continue growing double digit in the countries where it is now present in Europe.
    Show source
    Second, just given the pipeline that VISUfarma has in the ophthalmology front, we expect the business in the ophthalmology side continue to grow double digit in the countries that we are now present in Europe.
  • The company plans to file Respimat and Etanercept in the current fiscal year; Lupin has nearly completed the Etanercept dossier, with very little work remaining before filing.
    Show source
    Vinita Gupta: So Respimat is actually in the works right now and will be a current fiscal year filing and the Etanercept also will be in the current fiscal year.
  • The company plans eight to nine US product filings in FY27 on the respiratory front.
    Show source
    For the US we have, eight to nine product filings in FY27 on the respiratory front.
  • The company was not certain it would see additional competition for Spiriva in FY27, despite being aware that some companies had said they filed products.
    Show source
    I mean we have been aware about some companies talking about the fact that they have filed products but just given how long it takes to get these products right, we're not certain that we would see additional competition in FY27.
  • The company said potential competition for Tolvaptan and possibly Mirabegron next year would impact its overall margins, and that an expected increase in R&D expenditure was also reflected in its guidance.
    Show source
    So that would actually in some ways impact our overall margins.
  • The company expected U.S. revenues to see high single-digit or low double-digit erosion compared with the current year, based on anticipated competition in products such as Mirabegron and Tolvaptan; injectable launches and Pegfilgrastim were expected to offset some erosion, and Lupin expected its U.S. base business to grow.
    Show source
    We think that based on the competition that we foresee in products like Mirabegron and Tolvaptan, we should be able to get to a level compared to the current year where maybe it's a high single digit or low double-digit erosion in terms of revenues.
  • The company expected U.S. revenues to be a billion dollar plus in FY27.
    Show source
    Vinita Gupta: In FY27 to be a billion dollar plus.
  • The company had like nine products in the current fiscal year and said it would provide the products and actual filing timelines in the next quarter or so. Replaced by a later filing.
    Show source
    Vinita Gupta: Like I mentioned, we have like nine products in the current fiscal year.
  • The company said it was pleased with its team's performance in FY26 and would continue working to exceed its own and market expectations in FY27 and beyond. Replaced by a later filing.
    Show source
    As mentioned, we've been very pleased with the performance our team has been able to deliver in FY26 Page 17 of 18 May 8, 2026 and continue to work hard to be able to exceed both our expectations as well as the market expectations in FY27 and beyond.

What it is building and selling

Projects and capacity

  • The company was working on green propellant MDIs. Replaced by a later filing.
    Show source
    And we’re also ourself working on the green propellant MDIs.

Demand and pricing

  • The company believes there is still an opportunity in Ranibizumab despite part of the market shifting to Aflibercept, and says its product has both a pre-filled syringe and a vial while the majority of competitors have vial only, differentiating it in the marketplace.
    Show source
    So, we also see an opportunity for our product to be differentiated in the marketplace.
  • The company has already launched Semaglutide in India and identifies South Africa and Brazil as other important markets, with these three markets expected to start it off.
    Show source
    But these three markets will probably start it off for us.
  • The company sees an attractive Semaglutide opportunity in Emerging Markets even as a latecomer, supported by its market presence in diabetes and metabolic products including Dapagliflozin and Empagliflozin launches in Brazil; Lupin says pure generic markets will be tougher.
    Show source
    We see a good opportunity even as a late comer and I think in the pure generic markets it will be tougher, but in the Emerging Markets it should continue to be an attractive opportunity for us.
  • The company did not expect GSK's launch of a green Albuterol inhaler to adversely affect other Albuterol inhalers on the market; it thought the branded version of Ventolin® could expand the Albuterol market.
    Show source
    That's what we've been able to tell because based on what we learnt and we hope that it actually expands the market for Albuterol.

Segments

  • The company has first-to-file positions on exclusive dosage forms of Sacubitril Valsartan and Rivaroxaban.
    Show source
    We have Sacubitril Valsartan as well as Rivaroxaban both are exclusive dosage form that we have first to file on.
Show 6 more statements

Segments

  • The company identified Pegfilgrastim, including its OBI different dosage form, Ranibizumab, Aflibercept and Etanercept in FY29 among its biosimilar products.
    Show source
    Vinita Gupta: Pegfilgrastim and Ranibizumab, the OBI which of course is Pegfilgrastim, but a different dosage form and Aflibercept and the fifth one is Etanercept in FY29.
  • The company said acceptance for its Semaglutide pen was pretty solid. Replaced by a later filing.
    Show source
    As far as device is concerned, I think the acceptance for the pen is pretty solid and I'm glad that we're playing that.

Deals and partners

  • The company is pursuing Semaglutide through partnerships in markets such as Canada.
    Show source
    Through partnerships in markets like Canada and the like as well.
  • The company had not been able to keep up with demand for Risperdal Consta® because it manufactured the product as a CMO and had struggled to ramp up; the brand and Teva's supplier had also had supply issues, leaving a marketplace gap and incremental demand that Lupin was trying to meet.
    Show source
    So, there's a real gap in the marketplace which is a nice problem to have and we're trying to see how we can best meet the incremental demand.
  • The company had multiple products on its platform for other brands and a few ongoing conversations about potentially doing innovative product transactions using the platform.
    Show source
    So, at this point in time, we have multiple products on for other brands in the platform and have a few conversations ongoing on potentially doing innovative product transactions with the platform.
  • The company had a couple of its own innovative products on the platform and had partner interest in co-developing long-acting versions of partners' products.
    Show source
    We have couple of our own innovative products in the platform as well as interest from partners to work with us on co developing, long-acting versions of their products.

Everything else said on the call

Group structure

  • The VISUfarma acquisition expands Lupin's presence from the UK, Germany and France to Italy and Spain, where Lupin previously had no presence.
    Show source
    Number one, geographically, it expands our presence from UK, Germany, France to Italy and Spain markets where we had no presence in.
  • The company sees an opportunity to leverage its ophthalmology portfolio, respiratory products, biosimilars and NaMuscla® in Italy and Spain to expand its footprint in Europe.
    Show source
    And just leveraging the presence across the ophthalmology portfolio, taking our respiratory products, our biosimilars, NaMuscla® into this market is a real opportunity for us that we see as a potential of growing our overall footprint in Europe.
  • The company sees potential to leverage the VISUfarma portfolio in Latin America and Southeast Asia.
    Show source
    But in Latin America and Southeast Asia, we have the potential of leveraging the VISUfarma portfolio into these markets.
  • Team is looking at whether the VISUfarma portfolio can be launched in some Developed Markets. Replaced by a later filing.
    Show source
    And our team is also looking to see whether we can launch in some of the Developed Markets.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Tushar Manudhane: Just a clarification on guidance for FY27. Madam highlighted high single digit revenue growth with 25% EBITDA margin?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: That's correct. We did say that we would be looking at around about 25%, or in the vicinity of that for the full year and of course high-single digit number in terms of overall sales growth.

  2. Question

    Tushar Manudhane: So, effectively are you sort of factoring the competition for like Tolvaptan kind of a product and which is why you see EBITDA margin lowering down in FY27 ?

    Answer, vinita gupta

    Vinita Gupta: Yes, we have factored that in both competition for Mirabegron as well as Tolvaptan. Tushar Manudhane: And just as far as Q4 is concerned, compared to Q3 FY26 while the revenue have sort of moved up on absolute basis. But EBITDA has moved down. Is it to do with the U.S business profitability going down or ex-US geographies EBITDA moving down?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: There are two parts to that. Essentially the EBITDA margins decline because of there's a slightly increased, manpower cost, as you can see. The second is essentially, we have captured what we have, paid out Astellas on account of Mirabegron settlement as part of the manufacturing other expenses line that's also included. And there's of course the component of foreign exchange that's been captured out there.

  3. Question

    Tushar Manudhane: So, it's largely to do with this US Mirabegron related aspect which has sort of dragged the EBITDA on a QoQ basis?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: On the Other expenses line.

  4. Question

    Neha Manpuria: How should we think about the US business in the next year given what you mentioned about Tolvaptan and Mirabegron? Do you see any other product launches which could be meaningful? I know it's difficult to sustain this base, but even as we see competition in Tolvaptan and Mirabegron, what sort of product launches should we look forward to over the next two years which probably gives us the confidence on 25% margin?

    Answer, vinita gupta

    Vinita Gupta: So, with Tolvaptan and Mirabegron as well, apart from, the additional competition, we still see the generic market growing, jus t given the generic penetration in Tolvaptan is under 40% and then Mirabegron is just reaching 50% right now. So, there is a potential for additional generic penetration and expansion of the marketplace despite additional competition. So that's one. So, we do expect them to be material contributors especially in FY27. Apart from that, I think in th e next fiscal year, o ur Ravicti® product, the Glycerol Phenylbutyrate (“ GPB”) is a material product for us in FY27. We have Saxenda® that we hope to launch in the second half of the year, which would Page 8 of 18 May 8, 2026 be a material product for us. So, we have 20 plus products.

    Answer, vinita gupta

    We have two first to files as well. We have Sacubitril Valsartan as well as Rivaroxaban both are exclusive dosage form that we have first to file on. And then another big opportunity as we look at it right now for FY27 is Pegfilgrastim for us.. We've just entered into partnership with Valorum and expect that from Q2 and Q3 onwards will start ramping up and be a material contributor to the fiscal year. So, I'm giving you a question about the next two years. In FY28, we see potentially the impact of both full year impact of Pegfilgrastim as well as Ranibizumab that we expect to launch later in FY27. That should be a material opportunity for us in FY28.

    Answer, vinita gupta

    We are in the final stages with Dulera at this point, just responding to the last query from the FDA and would expect that product to be in the market in FY28 plus we have a material 505(b)(2) Apixaban new dosage form that we filed to the agency. We expect that to come to the market in FY28. So yeah, a good number of product launches, some exclusive first to files, good impact of the biosimilars and 505(b)(2) .

  5. Question

    Neha Manpuria: My second question is, I think, Ramesh sir mentioned about capital allocation. Given the increase in cash balance which will only go up with this, these US launches, how should we think about capital allocation priorities? I know, you've mentioned this in the past. I just wanted to get a sense of, what we are seeing, in terms of opportunities in the market ? What's interesting you and what are the challenges in terms of not being able to deploy that money?

    Answer, vinita gupta

    Vinita Gupta: We of course would like the right opportunity so we can deploy the capital effectively, but remain very focused in really allocating material portion of our capital to assets either on the specialty side of the business for the Developed Markets like this VISUfarma acquisition, or assets that can complement us in India both in our existing therapy areas as well as bolster the therapy areas that we want to build. So, we continue to be very focused in, looking for assets in the specialty segments that we've identified. Now that we have transacted on VISUfarma, we are seeing a high flow of ophthalmology assets which could be pretty interesting for us and likewise continue to look for pulmonology as well as rare neuro assets.

  6. Question

    Neha Manpuria: So, on the specialty side, the dearth of assets is not an issue? There are enough and more that you can look at. So, it's about us selecting the assets that we want?

    Answer, vinita gupta

    Vinita Gupta: Yes, it's really finding the right assets that from a risk standpoint meet our internal criteria as well as give us enough in terms of potential to be meaningful to grow our specialty business.

  7. Question

    Bino Pathiparampil: Vinita given the settlement, is it fair to assume that in Q4 you have sold significantly more Mirabegron compared to Q3?

    Answer, vinita gupta

    Vinita Gupta: No, they haven't entered the market yet. We believe that they are waiting for product supply. Bino Pathiparampi l: Coming to Tolvaptan, what is the timeline for competition entry that you are now looking at? I believe there is a patent expiring in September this year. Is that a relevant timeline ?

    Answer, vinita gupta

    Vinita Gupta: Yes, that is the timeline that we have taken into account in our plans.

  8. Question

    Bino Pathiparampil: One final question to Ramesh. The impact of PLI going away on other operating income, is that completely in the base now or will we see some more decline from these levels?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: No, I think more or less there'll be some PLI coming in next year as well.

  9. Question

    Damayanti Kerai: My first question is on VISUfarma. So earlier you mentioned this will add around Euro 50 million - 60 million sales on top line and 25% margin. So just want to hear your thought on where do you look this business to grow in say, next two to three years and what will be the key focus segments here?

    Answer, vinita gupta

    Vinita Gupta: So, there are multiple areas where strategically the VISUfarma acquisition adds to us. Number one, geographically, it expands our presence from UK, Germany, France to Italy and Spain markets where we had no presence in. And just leveraging the presence across the ophthalmology portfolio, taking our respiratory products, our biosimilars, NaMuscla® into this market is a real opportunity for us that we see as a potential of growing our overall footprint in Europe. Second, just given the pipeline that VISUfarma has in the ophthalmology front, we expect the business in the ophthalmology side continue to grow double digit in the countries that we are now present in Europe. And third, the portfolio also has a fit in Other Emerging Markets for certain. And our team is also looking to see whether we can launch in some of the Developed Markets. But in Latin America and Southeast Asia, we have the potential of leveraging the VISUfarma portfolio into these markets.

    Answer, vinita gupta

    So multiple areas of synergies that our team is working upon and we remain confident that this is going to be a material step in enhancing our business in Europe as well as on the specialty front.

  10. Question

    Damayanti Kerai: And the top line should comfortably cross say USD 100 million mark in two to three years If all these factors play out well?

    Answer, vinita gupta

    Vinita Gupta: No, actually it came with an excellent team on the commercial side as well as marketing. Majority of the team we have on boarded into Lupin to be able to build on the current ophthalmic model, but also expand Lupin's other therapy areas into these regions .

Show 20 more questions
  1. Question

    Damayanti Kerai: Second question is on your settlement for Mirabegron with A stellas. So you had one prepaid component which I believe is sitting in Q4 numbers. And on an ongoing basis you will be paying per unit cost. And that will be part of the ongoing operating expense ?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: Yeah, there are two parts to that. There is one element which of course will be captured as part of manufacturing and other expenses. And the second part, it actually gets amortized over a period of time.

  2. Question

    Damayanti Kerai: Any indication like which will be the bigger component, whether it's part of operating expense or the one which is amortized?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: Clearly, it depends on the sales at this stage. So , the first component is actually variable. The second is just an amortization spread over time .

    Answer, vinita gupta

    Vinita Gupta: And we have factored in the additional cost per unit in our Gross margin going forward. The amortization of the USD 75 million will be in the next two years . Damayanti Kerai : My last question is regarding one product which we earlier discussed. Dalbavancin. Can you update on the status of that particular product ?

  3. Question

    Vivek Agarwal: Couple of questions on biosimilars. One is on Ranibizumab, so how comfortable you are with the economics of this product? If you look at the current market dynamics, the prescriptions have shifted to Aflibercept that is a longer duration and if you look at the existing or the current incumbents’ biosimilars, they have dropped this product right from the market. So, what gives you confidence that this product is going to be a material product for you?

    Answer, vinita gupta

    Vinita Gupta: We actually are seeing a good amount of traction with the FDA in getting a product to market. The other companies have had challenges in product supply and we think that has been part of the reason why the product is out of the market. Also, I think you're going to see companies relaunching Ranibizumab. So, we do believe that while part of the market has shifted into Aflibercept, there's still an opportunity in Ranibizumab. Also, for us we have both the pre-filled syringe as well as the vial while majority of the competitors have vial only. So, we also see an opportunity for our product to be differentiated in the marketplace.

  4. Question

    Vivek Agarwal: You talk about let's say around four products in the biosimilar. Which are the other two products if it is possible for you to highlight?

    Answer, vinita gupta

    Vinita Gupta: Pegfilgrastim and Ranibizumab, the OBI which of course is Pegfilgrastim, but a different dosage form and Aflibercept and the fifth one is Etanercept in FY29.

  5. Question

    Vivek Agarwal: One more question on biosimilars in the next couple of years, w hat kind of the revenues that you estimate from the sales of biosimilars only in the U S?

    Answer, vinita gupta

    Vinita Gupta: We haven't called out the actual revenues from biosimilars, but they're meaningful. Each product is pretty meaningful in our P&L going forward. W e really look at the biosimilars opportunity as a very similar to our respiratory opportunity over the next five years.

  6. Question

    What's the timeline with respect to filing for these product and when should we expect launch ?

    Answer, vinita gupta

    Vinita Gupta: So Respimat is actually in the works right now and will be a current fiscal year filing and the Etanercept also will be in the current fiscal year. We pretty much have the entire dossier for Etanercept. There's very little work to be done to be able to file it. There are other material products that we are planning to launch. For the US we have, eight to nine product filings in FY27 on the respiratory front.

  7. Question

    Saion Mukherjee: On Ellipta, any timeline for that?

    Answer, vinita gupta

    Vinita Gupta: Ellipta, we are still working on it. It's been challenging for us, but we continue to work on both the Breo and Trelegy products.

  8. Question

    Kunal Randeria: The first question is on Semaglutide opportunity across Emerging Markets. Are there any particular markets that you would like to call out that can make a meaningful contribution in the next couple of years?

    Answer, nilesh gupta

    Nilesh Gupta: I think the big market for us is India. Obviously, you know, we've already launched in India. I think South Africa would be the other important market, Brazil as well. Through partnerships in markets like Canada and the like as well. But these three markets will probably start it off for us.

  9. Question

    Kunal Randeria: Would you like to maybe give more colour on India, obviously you have launched, but what about Brazil, Canada, some timelines?

    Answer, vinita gupta

    Vinita Gupta: Brazil and Canada should really be filing this year, so launch hopefully next year.

  10. Question

    Kunal Randeria: But the fact is that you may not be among the first wave. So, will it still be meaningful?

    Answer, vinita gupta

    Vinita Gupta: We think in the Emerging Markets where we have really built a market presence on the diabetes - metabolic front, like I mentioned Brazil, with the Dapagliflozin launch and now Empagliflozin launch, we're really creating a good position in the metabolic space. We see a good opportunity even as a late comer and I think in the pure generic markets it will be tougher, but in the Emerging Markets it should continue to be an attractive opportunity for us.

  11. Question

    Kunal Randeria: The second question on biosimilars, so I understand, you'll have Pegfilgrastim and maybe Etanercept a few years down the line in the US but the entry barrier now for biosimilars is going down, the cost is going down. So , I'm sure a lot more players would come in. Do you maybe envisage a situation where the price erosion might be a lot steeper than what you are currently f actoring in, let's say by FY29 - FY30? Page 13 of 18 May 8, 2026 Vinita Gupta: I think unless there's a real material shift in the market model, we really see the new entrants bringing an advantage to the overall economics in the biosimilar segment.

    Answer, vinita gupta

    And from our perspective, the f irst few products that we have obviously we've been working on these for five plus years. But as we look at the future pipeline, informed by the reducing hurdles from a regulatory perspective and easier go - to - market access in the US . Also equally we are finding in Europe as well there is a more efficient model, especially where country like Germany is starting to tender biosimilar products as well. We see an opportunity for products where we are in the first wave and that have limited number of competitors. So, our focus from pipeline perspective is really on products where we can be in the first wave or limited number of competitors that can give us a unique positioning. We have a good positioning on the ophthalmology front beyond biosimilars with VISUfarma and other products that we are planning to bring into the market. So, we think it really enables us, as an ophthalmic player to bring in both the affordable biosimilars as well as innovative products.

    Answer, vinita gupta

    But beyond that, the other pipeline that we are investing in for the future is a very selective pipeline that we're going after.

  12. Question

    Kunal Randeria: Just how big is the biosimilar franchise as of now from a revenue perspective?

    Answer, nilesh gupta

    Nilesh Gupta: It’s about USD 50 million right now but slated to be multiple times this financial year itself.

  13. Question

    Shashank Krishnakumar: The first one was on Spiriva. I just wanted to check if you're hearing anything incrementally in terms of competition there and whether our FY27 guidance, sort of any potential generic?

    Answer, vinita gupta

    Vinita Gupta: We don't know for certain. I mean we have been aware about some companies talking about the fact that they have filed products but just given how long it takes to get these products right, we're not certain that we would see additional competition in FY27.

  14. Question

    Shashank Krishnakumar: And just the last one on Ellipta. So just wanted to check on the challenges that we're facing. Is it with respect to the device? I think one of our also recently Page 14 of 18 May 8, 2026 entered a partnership for the device. So where exactly is the challenge? If you could sort of, explain what is the hurdle in terms of the filing?

    Answer, nilesh gupta

    So good start. But very early days, right? I mean you're talking about nine days of data and that's, next week we'll have data for April as well. We've obviously had substantial increase in primary in the second month. But time will show. But, I think our goal is very clear to be at Top 3 player in this as generic Semaglutide and I think we're well on track. As far as device is concerned, I think the acceptance for the pen is pretty solid and I'm glad that we're playing that.

  15. Question

    Shyam Srinivasan: My last question just again back on the margin guidance. Right so we're going from 29% this year to 25% let's assume. But Q4 had some headwinds already given that we had a settlement and maybe some of it played through in Q4 as well. So is there extra sprinkling of conservativeness in our margins or you think during the year there could be upside surprises as well? Page 15 of 18 May 8, 2026 Ramesh Swaminathan: No, this is actually as a result of we reckon ed that there could be some competition coming in for Tolvaptan and possibly for Mirabegron next year.

    Answer, ramesh swaminathan

    So that would actually in some ways impact our overall margins. And of course as you would see our R&D expenditure is stated to increase a bit. So that is also being captured in the overall guidance.

  16. Question

    Vishal Manchanda: On the Albuterol inhaler market, wanted to check whether you expect any adverse impact on account of the GSK launch. So, they are supposed to launch a green inhaler around third quarter of this financial year. Do you think the other Albuterol inhalers on the market will see an adverse impact?

    Answer, vinita gupta

    Vinita Gupta: We don't think so. We think that their product is really going to be a branded version of Ventolin®. That's what we've been able to tell because based on what we learnt and we hope that it actually expands the market for Albuterol. And we’re also ourself working on the green propellant MDIs. So, we're looking forward to see how the launch goes and we'll track it very closely.

  17. Question

    Vishal Manchanda: Any filing timelines?

    Answer, vinita gupta

    Vinita Gupta: Like I mentioned, we have like nine products in the current fiscal year. So, it's a material year for us with all the work the team has done over the last couple of years. We'll come back in the next quarter or so with the products and actual filing timelines.

  18. Question

    Vishal Manchanda: Just another one on Risperdal Consta®. If you could share how the product is doing and whether you intend to file other long-acting injectable products based on your know-how on Risperdal Consta®?

    Answer, vinita gupta

    Vinita Gupta: The product has done well so far. Actually, we've not been able to keep up with the demand. We manufactured the product as a CMO and have struggled to really ramp up. The brand has had supply issues as well. So, there has been an increased demand in the marketplace that they're trying to work hard to see how we can leverage our position. Also, Teva had supply issues with their supplier of the product as well. So, there's a real gap in the marketplace which is a nice problem to have and we're trying to see how we can best meet the incremental demand.

    Answer, vinita gupta

    As far as the platform goes, while we worked first on a Page 16 of 18 May 8, 2026 generic, as we looked at the potential of the platform, there are multiple innovative products where the platform can be very valuable. So, at this point in time, we have multiple products on for other brands in the platform and have a few conversations ongoing on potentially doing innovative product transactions with the platform.

  19. Question

    Vishal Manchanda: You mean doing your own innovative products or doing that as a CDMO partner?

    Answer, vinita gupta

    Vinita Gupta: We have both. We have couple of our own innovative products in the platform as well as interest from partners to work with us on co developing, long-acting versions of their products.

  20. Question

    Vivek Agarwal: Just one question on the overall U.S business, right. We have done close to USD 1.3 billion of revenues this year and then there are a lot of moving parts. Couple of products will come down in FY27 and then we will see some kind of additional competition, additional erosion in FY28 as well. So, it would be helpful if you just give some ballpark number of US revenues for FY27 and FY28 to work with?

    Answer, vinita gupta

    Vinita Gupta: In the past we've said that we should be able to sustain the bi llion dollar plus at this point. We think that based on the competition that we foresee in products like Mirabegron and Tolvaptan, we should be able to get to a level compared to the current year where maybe it's a high single digit or low double-digit erosion in terms of revenues. And that's of course a combination of the current products as well as new product launches. With our injectable launches as well as with Pegfilgrastim, we expect to offset some of the erosion and we expect our base business also to grow in the US. Vivek Agarwal: If I heard correctly, right in FY28 if you are expecting that U .S business to be a billion dollar plus. Close to billion dollars plus?

    Answer, vinita gupta

    Vinita Gupta: In FY27 to be a billion dollar plus.

    Answer, vinita gupta

    Vinita Gupta: Thank you, friends for all your questions. Hopefully we've been able to answer all of them. Otherwise, we will take them offline. As mentioned, we've been very pleased with the performance our team has been able to deliver in FY26 Page 17 of 18 May 8, 2026 and continue to work hard to be able to exceed both our expectations as well as the market expectations in FY27 and beyond. Thank you again.

Questions about this call

When was the Lupin Q4 FY26 earnings call transcript filed?
Lupin filed the transcript with the exchange on 14 May 2026. This page is built from that transcript.
What does this page list?
37 statements from the transcript across 8 topics, 6 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 30 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Lupin Q4 FY26 concall: Lupin expects high-single digit overall sales growth and an EBITDA margin around 25% or in the vicinity of that for the full year · DalalOS